(MASI) Masimo - Overview
Sector: Healthcare | Industry: Medical Devices | Exchange: NASDAQ (USA) | Market Cap: 9.355m USD | Total Return: 13.6% in 12m
Avg Turnover: 153M
EPS Trend: 82.4%
Qual. Beats: -2
Rev. Trend: -86.7%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
Supp Ema20
Masimo Corporation (NASDAQ: MASI) specializes in noninvasive patient monitoring technologies, hospital automation, and connectivity solutions. The company’s core business centers on its proprietary Signal Extraction Technology (SET), which improves the accuracy of pulse oximetry during patient motion and low perfusion. Its product portfolio extends to brain function monitoring, hemodynamic tracking, and telehealth platforms, serving clinical environments ranging from hospitals to home care.
Operating within the Health Care Equipment sector, Masimo utilizes a multi-channel distribution model involving direct sales, third-party distributors, and original equipment manufacturer (OEM) partnerships. The medical device industry typically requires significant research and development investment to navigate stringent regulatory approval processes and maintain intellectual property protections. Masimo’s integration of hardware with automation software creates a recurring ecosystem for healthcare providers seeking to improve patient safety and workflow efficiency.
Investors analyzing the companys long-term valuation and market position may find additional data on ValueRay useful for further due diligence.
- Hospital adoption of SET pulse oximetry drives recurring sensor revenue growth
- Strategic separation of consumer audio business impacts long-term operating margins
- Legal disputes and patent litigation settlements influence cash flow and valuation
- Expansion of hospital automation software increases high-margin subscription service revenue
- Regulatory approval timelines for new noninvasive monitoring devices dictate market entry
| Net Income: 76.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.13 > 0.02 and ΔFCF/TA 6.73 > 1.0 |
| NWC/Revenue: 34.98% < 20% (prev 35.00%; Δ -0.03% < -1%) |
| CFO/TA 0.14 > 3% & CFO 232.0m > Net Income 76.3m |
| Net Debt (395.2m) to EBITDA (344.5m): 1.15 < 3 |
| Current Ratio: 2.68 > 1.5 & < 3 |
| Outstanding Shares: last quarter (52.6m) vs 12m ago -4.01% < -2% |
| Gross Margin: 61.73% > 18% (prev 0.52%; Δ 6.12k% > 0.5%) |
| Asset Turnover: 79.20% > 50% (prev 79.42%; Δ -0.22% > 0%) |
| Interest Coverage Ratio: 10.01 > 6 (EBITDA TTM 344.5m / Interest Expense TTM 30.6m) |
| A: 0.33 (Total Current Assets 870.5m - Total Current Liabilities 325.4m) / Total Assets 1.64b |
| B: 0.85 (Retained Earnings 1.40b / Total Assets 1.64b) |
| C: 0.16 (EBIT TTM 306.2m / Avg Total Assets 1.97b) |
| D: 1.62 (Book Value of Equity 1.38b / Total Liabilities 853.8m) |
| Altman-Z'' = 7.70 = AAA |
| DSRI: 0.97 (Receivables 288.9m/346.6m, Revenue 1.56b/1.82b) |
| GMI: 0.84 (GM 61.73% / 52.12%) |
| AQI: 0.72 (AQ_t 0.23 / AQ_t-1 0.33) |
| SGI: 0.86 (Revenue 1.56b / 1.82b) |
| TATA: -0.09 (NI 76.3m - CFO 232.0m) / TA 1.64b) |
| Beneish M = -3.56 (Cap -4..+1) = AAA |
As of May 27, 2026, the stock is trading at USD 178.67 with a total of 880,376 shares traded.
Over the past week, the price has changed by -0.07%,
over one month by +0.01%,
over three months by +1.97% and
over the past year by +13.62%.
Masimo has received a consensus analysts rating of 4.11. Therefore, it is recommended to buy MASI.
- StrongBuy: 4
- Buy: 2
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 180 | 0.7% |
P/E Trailing = 44.2178
P/E Forward = 40.8163
P/S = 6.0027
P/B = 11.8599
P/EG = 4.8334
Revenue TTM = 1.56b USD
EBIT TTM = 306.2m USD
EBITDA TTM = 344.5m USD
Long Term Debt = 445.7m USD (from longTermDebt, last quarter)
Short Term Debt = 14.5m USD (from shortTermDebt, last quarter)
Debt = 519.8m USD (from shortLongTermDebtTotal, last quarter) + Leases 33.9m
Net Debt = 395.2m USD (calculated: Debt 519.8m - CCE 124.6m)
Enterprise Value = 9.75b USD (9.36b + Debt 519.8m - CCE 124.6m)
Interest Coverage Ratio = 10.01 (Ebit TTM 306.2m / Interest Expense TTM 30.6m)
EV/FCF = 46.70x (Enterprise Value 9.75b / FCF TTM 208.8m)
FCF Yield = 2.14% (FCF TTM 208.8m / Enterprise Value 9.75b)
FCF Margin = 13.40% (FCF TTM 208.8m / Revenue TTM 1.56b)
Net Margin = 4.90% (Net Income TTM 76.3m / Revenue TTM 1.56b)
Gross Margin = 61.73% ((Revenue TTM 1.56b - Cost of Revenue TTM 596.5m) / Revenue TTM)
Gross Margin QoQ = 62.14% (prev 59.95%)
Tobins Q-Ratio = 5.94 (Enterprise Value 9.75b / Total Assets 1.64b)
Interest Expense / Debt = 5.89% (Interest Expense 30.6m / Debt 519.8m)
Taxrate = 21.04% (15.0m / 71.3m)
NOPAT = 241.8m (EBIT 306.2m * (1 - 21.04%))
Current Ratio = 2.68 (Total Current Assets 870.5m / Total Current Liabilities 325.4m)
Debt / Equity = 0.66 (Debt 519.8m / totalStockholderEquity, last quarter 788.9m)
Debt / EBITDA = 1.15 (Net Debt 395.2m / EBITDA 344.5m)
Debt / FCF = 1.89 (Net Debt 395.2m / FCF TTM 208.8m)
Total Stockholder Equity = 840.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.88% (Net Income 76.3m / Total Assets 1.64b)
RoE = 9.08% (Net Income TTM 76.3m / Total Stockholder Equity 840.7m)
RoCE = 23.80% (EBIT 306.2m / Capital Employed (Equity 840.7m + L.T.Debt 445.7m))
RoIC = 20.03% (NOPAT 241.8m / Invested Capital 1.21b)
WACC = 6.93% (E(9.36b)/V(9.88b) * Re(7.06%) + D(519.8m)/V(9.88b) * Rd(5.89%) * (1-Tc(0.21)))
Discount Rate = 7.06% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 4.60 | Cagr: -0.92%
[DCF] Terminal Value 77.97% ; FCFF base≈180.2m ; Y1≈206.5m ; Y5≈303.9m
[DCF] Fair Price = 79.79 (EV 4.57b - Net Debt 395.2m = Equity 4.18b / Shares 52.4m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 82.37 | EPS CAGR: 24.43% | SUE: -2.21 | # QB: -2
Revenue Correlation: -86.67 | Revenue CAGR: -10.11% | SUE: 0.16 | # QB: 0
EPS current Quarter (2026-06-30): EPS=1.41 | Chg30d=+0.00% | Revisions=N/A | Analysts=1
EPS next Quarter (2026-09-30): EPS=1.44 | Chg30d=+0.00% | Revisions=N/A | Analysts=1
EPS current Year (2026-12-31): EPS=5.95 | Chg30d=+1.54% | Revisions=+20% | GrowthEPS=+0.0% | GrowthRev=+6.6%
EPS next Year (2027-12-31): EPS=6.60 | Chg30d=+0.53% | Revisions=+20% | GrowthEPS=+10.9% | GrowthRev=+7.3%
[Analyst] Revisions Ratio: +20%